Showing results (91-100 of 106) with videos related to
Sort By:
Pageof 11
Epilepsia|January 1, 1990
Effects of carbamazepine on psychomotor performance in children as a function of drug concentration, seizure type, and time of medicationM G Aman, J S Werry, J W Paxton, et al.Cancer Chemotherapy and Pharmacology|January 1, 1992
Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouseJ W Paxton, D Young, S M Evans, et al.Neurochemical Research|May 1, 1993
Blood-brain glucose transfer in the mouseE M Cornford, D Young, J W Paxton, et al.The Analyst|July 1, 1996
Enzyme linked immunosorbent assay for detecting benzodiazepines in urineD Laurie, A J Mason, N H Piggott, et al.Drug Metabolism and Drug Interactions|January 1, 1988
Thiolytic cleavage and binding of the antitumour agent CI-921 in bloodP Kestell, J W Paxton, I G Robertson, et al.Biochemical Pharmacology|October 24, 1991
Cytosol mediated metabolism of the experimental antitumor agent acridine carboxamide to the 9-acridone derivativeI G Robertson, B D Palmer, M Officer, et al.Cancer Research|January 1, 1992
Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brainE M Cornford, D Young, J W Paxton, et al.Cancer Chemotherapy and Pharmacology|September 6, 2000
Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomideP Kestell, L Zhao, B C Baguley, et al.Cancer Chemotherapy and Pharmacology|October 6, 2006
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trialM B Jameson, B C Baguley, P Kestell, et al.Cancer Research|February 1, 1990
Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in miceP Kestell, J W Paxton, P C Evans, et al.Pageof 11